Zhilong Huoxue Tongyu capsule inhibits rabbit model of hyperlipidemia and atherosclerosis through NF-κB/NLRP3 signaling pathway

OBJECTIVE: Zhilong Huoxue Tongyu capsule (ZL) is a Chinese patent medicine for treating cardio-cerebral diseases. However, the pharmacological mechanism by which it regulates blood lipids and treats atherosclerosis (AS) is unclear. Therefore, the purpose of this study is to explore the mechanism of...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Mengnan, Wang, Raoqiong, Chen, Mingtai, Hu, Zhongjing, Han, Mei, Mazhar, Maryam, Xue, Jinyi, Zou, Yuan, Wu, Qibiao, Yang, Sijin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643091/
https://www.ncbi.nlm.nih.gov/pubmed/38027979
http://dx.doi.org/10.1016/j.heliyon.2023.e20026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643091/
https://www.ncbi.nlm.nih.gov/pubmed/38027979
http://dx.doi.org/10.1016/j.heliyon.2023.e20026

Ejemplares similares